hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06326528 id: SGLT2 inhibitors briefTitle: SGLT2 Inhibitors and Perioperative Period overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-04-01 date: 2025-10-01 date: 2024-03-22 date: 2024-03-22 name: Assiut University class: OTHER briefSummary: The expanded use of SGLT2 inhibitors motivates us to assess the role of SGLT2 inhibitors in perioperative period on patients who will undergo cardiac surgery in Assiut University. conditions: Perioperative Complication studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: SGLT2 inhibitor measure: Difference of cardiac function by speckle tracing between patients who will receive SGLT2 and patients who not. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06326515 id: Government College University briefTitle: Cognitive Behavior Therapy for Depression, Stigmatization, Criminogenic Cognition, and Quality of Life Among Patients With Opioid Use Disorder (OUD): A Randomized Control Trial. acronym: CBT with OUD overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-01 date: 2024-07-20 date: 2024-09-10 date: 2024-03-22 date: 2024-03-22 name: Government College University Faisalabad class: OTHER briefSummary: to investigate the impact of cognitive behavior therapy for psychiatric problems among patients with opioid use disorder with relapse condition.
In this randomize control trail (RCT), N=120 patients with relapse condition would be taken. After enrolment patients' eligibility assessment would be completed and then n=60 patients would be allocated to experimental (n=30) and waitlist control (n=30) through random assignment. Patient's age range would be between 20 to 30 years. conditions: Psychoeducation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized control trial design would be used in this study. It would be two arm study and there would be two groups an experimental and wait-list control group. Experimental group will receive intervention and another group would be placed in waitlist. In this research, parallel group design would be used. We will give treatment to all participants in a parallel way. Allocation ratio and framework would be equivalence i.e., treatment group and control group would be equal number of participants primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: psychoeducation name: Stigma Reduction and Relapse Management measure: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST; Henry-Edwards et al., 2003; Hussain et al., 2022). measure: Criminogenic Cognition Scale (CCS;Tangney, at el, 2012; Jamil & Fatima, 2018): measure: Patient Health Questionnaire (PHQ-9; Robert et al. 1999; Ahmad et al, 2018). measure: Relapse Risk Scale (RRS; Marlatt & Gordon, 1985; Hussain et al., 2016): measure: Perceived Stigma of Addiction Scale measure: Brief Cope Inventory (BCI) measure: World Health Organization Quality-of-Life Scale sex: ALL minimumAge: 20 Years maximumAge: 30 Years stdAges: ADULT facility: Dr Khalid Mahmood city: Faisalābad state: Punjab country: Pakistan lat: 31.41554 lon: 73.08969 hasResults: False
nctId: NCT06326502 id: 22ETN101-2IND001 briefTitle: A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma overallStatus: RECRUITING date: 2024-02-07 date: 2027-03-07 date: 2027-06-07 date: 2024-03-22 date: 2024-03-27 name: Etnova Therapeutics Corp. class: INDUSTRY briefSummary: ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor beta. Both in vitro and in vivo studies showed that ETN101 treatment/administration inhibited cancer cell survival and proliferation. In animal models, ETN101 had antitumor activity when administered to animals that did not respond to conventional targeted anticancer agents. conditions: Hepatocellular Carcinoma conditions: Advanced Hepatocellular Carcinoma conditions: Liver Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: ETN101 measure: Dose-limiting Toxicity (DLT) sex: ALL minimumAge: 19 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital status: RECRUITING city: Seoul zip: 03080 country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Severance Hospital status: RECRUITING city: Seoul zip: 03722 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06326489 id: 105122023-1/05.12.2023 id: ERP-2023-13520 type: OTHER_GRANT domain: Medtronic briefTitle: Evaluating the Efficacy and Quality of Life Impact of Transitioning to Advanced Hybrid Closed-Loop Insulin Pump Therapy in Romanian Children With Type 1 Diabetes Mellitus overallStatus: RECRUITING date: 2024-03-11 date: 2024-08-30 date: 2024-11-30 date: 2024-03-22 date: 2024-03-26 name: ELIAS Emergency University Hospital class: OTHER briefSummary: The proposed study aims to demonstrate the potential benefits of transitioning T1DM children from predictive low glucose suspend insulin pump therapy to advanced hybrid closed-loop insulin pump therapy in Romania. Primary Outcome: Variations in HbA1c between baseline visit (V1 - 740G) and assessment visit following three months of 780G insulin pump therapy (V2 - 780G).
Secondary Outcomes: changes in insulin requirements, time in range (TIR) levels, time below range (TBR), coefficient of variation (CV), frequency of severe hypoglycemic and hyperglycemic events requiring hospitalization, and PedsQL SF15 questionnaire scores. conditions: Diabetes Mellitus, Type 1 studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The study will include 30 children with type 1 diabetes aged seven years and older who use a predictive low glucose suspend insulin pump (740G). Patients eligible for the study will receive a 780G insulin pump for three months. primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Switching to the Medtronic 780G insulin pump measure: Variations in HbA1c measure: changes in insulin requirements measure: changes in time in range (TIR) levels measure: changes in time below range (TBR) measure: changes in coefficient of variation (CV) measure: changes in frequency of severe hypoglycemic and hyperglycemic events requiring hospitalization measure: changes in The Pediatric Quality of Life Inventory™ 4.0 Short Form 15 Generic Core Scales questionnaire scores sex: ALL minimumAge: 7 Years maximumAge: 17 Years stdAges: CHILD facility: Elias University Emergency Hospital status: RECRUITING city: Bucharest state: Sector 1 zip: 011461 country: Romania name: Sorin Ioacara, MD, PhD role: CONTACT phone: 0040213161600 email: drsorin@yahoo.com lat: 44.43225 lon: 26.10626 hasResults: False
nctId: NCT06326476 id: IRB-300012699 id: 000544067 type: OTHER domain: University of Alabama at Birmingham briefTitle: A Study to Demonstrate the Safety and Efficacy of Siplizumab in the Treatment of Hidradenitis Suppurativa overallStatus: NOT_YET_RECRUITING date: 2025-01 date: 2025-09-30 date: 2025-12-31 date: 2024-03-22 date: 2024-03-22 name: University of Alabama at Birmingham class: OTHER name: ITB-Med LLC briefSummary: This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa. conditions: Hidradenitis Suppurativa studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Siplizumab measure: Change in inflammatory lesion counts measure: Change in Hidradenitis Suppurativa Clinical Response (HiSCR) measure: Change in Hurley Stage measure: Change in Dermatology Life Quality Index (DLQI) scores measure: Improvement in Visual Analogue Scale (VAS) pain scores measure: Change in Lesion Counts sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06326463 id: DIRECT70 id: NCI-2024-03240 type: OTHER domain: NCI Clinical Trial Registration Program briefTitle: CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2030-07-01 date: 2031-07-01 date: 2024-03-22 date: 2024-04-12 name: St. Jude Children's Research Hospital class: OTHER briefSummary: The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse).
To evaluate the antileukemic activity of CD70-CAR T cells. We will determine the anti- leukemic activity of the CD70-CAR T cells in the bone marrow and in the treatment of extramedullary disease. conditions: Hematologic Malignancy conditions: ALL, Childhood conditions: AML, Childhood conditions: Lymphoma conditions: MDS studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Fludarabine name: Cyclophosphamide name: CD70-CAR T cell infusion (Autologous) name: Mesna measure: Maximum tolerated dose of CD70-CAR T cells sex: ALL maximumAge: 21 Years stdAges: CHILD stdAges: ADULT facility: St. Jude Children's Research Hospital city: Memphis state: Tennessee zip: 38105 country: United States name: Swati Naik, MD role: CONTACT phone: 866-278-5833 email: referralinfo@stjude.org lat: 35.14953 lon: -90.04898 hasResults: False
nctId: NCT06326450 id: 74626 briefTitle: Traditional In-Person Vs. Remote AR Clinical Simulation acronym: AR Brazil overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-05-31 date: 2025-05-31 date: 2024-03-22 date: 2024-04-12 name: Stanford University class: OTHER briefSummary: This is a non-inferiority, international, controlled trial that aims to evaluate the progression of physicians and residents through an Advanced Cardiac Life Support (ACLS) clinical simulated scenario. The study's primary objective is to compare the performance outcomes between two groups: participants in the traditional in-person simulation and those immersed in the Augmented Reality (AR) scenario conditions: Educational Problems studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 20 type: ESTIMATED name: Augmented Reality Headset measure: Progression through the ACLS clinical simulation demonstrated by NTS and TS measure: Demonstration of NTS during ACLS scenario measure: Evaluation of the AR system's usability measure: Exploration of perceptions, attitudes, and opinions of the AR simulation participants sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06326437 id: 1223 briefTitle: Dyadic Intervention for Psychological Distress of Patients With Colorectal Cancer and Their Spouses overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-06-01 date: 2024-07-01 date: 2024-03-22 date: 2024-03-22 name: Sun Yat-sen University class: OTHER briefSummary: The overall aim of the study is to evaluate the preliminary effect and feasibility of a dyadic intervention on mutuality, psychological strengths (i.e., illness cognition and dyadic coping), psychological distress, and QoL outcomes of patients with colorectal cancer and spouses. The colorectal cancer couples will be randomly allocated to the intervention group to receive a 6-week dyadic intervention, or to the control group to receive the usual care provided by the clinical team in the hospital. conditions: Colorectal Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: 6-week dyadic intervention measure: the Kessler psychological distress scale-10 measure: The Illness Cognition Questionnaire measure: Dyadic Coping Inventory measure: European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 measure: Locke-Wallace Marital Adjustment Scale sex: ALL minimumAge: 20 Years maximumAge: 59 Years stdAges: ADULT facility: The Sixth Affiliated Hospital of Sun Yat-sen University city: Guangzhou state: Guangdong zip: 510000 country: China name: Qian Sun role: CONTACT phone: +86 15616167998 email: sunq68@mail2.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06326424 id: 2023H0085 briefTitle: Delirium Identification in Older Patients With Alzheimer's and Other Related Dementias In the Emergency Department acronym: DELIRIUM overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2025-03-01 date: 2025-03-01 date: 2024-03-22 date: 2024-03-22 name: Ohio State University class: OTHER briefSummary: Delirium is highly prevalent and very bad for patients with dementia. Delirium is a dangerous medical condition that occurs in 6-38% of older Emergency Department patients and 70% of ICU patients. A person who develops delirium in the ED or hospital has a 12 times higher odds of being newly diagnosed with dementia in the next year compared to a similar patient who does not become delirious. Delirium is especially dangerous for persons living with Alzheimer Disease and Related Dementias (AD/ADRD). Persons living with ADRD have an almost 50% chance of developing delirium in the hospital.
The investigators propose integrating wrist biosensors into the emergency management of older adults with dementia. The investigators will monitor heart rate variability, movement, and electrodermal activity (electrical activity of at the level of the skin) to determine if an array of biosensors more sensitive to delirium than current verbal screening tools. conditions: Delirium conditions: Dementia conditions: Hospital Acquired Condition studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Empatica EmbracePlus measure: Proportion of participants who develop delirium measure: Intervention Acceptability measure: Biosensor data usability measure: Correlation of biosensor array data with clinical delirium sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: The Ohio State University Wexner Medical Center city: Columbus state: Ohio zip: 43210 country: United States lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06326411 id: NST-628-001 briefTitle: A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors acronym: NST-628 overallStatus: RECRUITING date: 2024-03 date: 2028-11 date: 2029-11 date: 2024-03-22 date: 2024-03-27 name: Nested Therapeutics, Inc class: INDUSTRY briefSummary: This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options. conditions: Oncology conditions: MEK Mutation conditions: RAF Gene Mutation conditions: Ras (KRAS or NRAS) Gene Mutation conditions: Melanoma conditions: NSCLC conditions: Glioma conditions: Solid Tumor, Adult conditions: MAPK Pathway Gene Mutation studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 230 type: ESTIMATED name: NST-628 measure: Part A and B: Evaluate the safety of NST-628 in patients with advanced solid tumors measure: Part A: Determine the recommended dose for expansion of NST-628 measure: Part B: Evaluate objective tumor response rate measure: Part A: Evaluate objective tumor response rate measure: Part A and B: Evaluate progression free survival (PFS) measure: Part A and B: Evaluate overall survival (OS) measure: Part A and B: Characterize the pharmacokinetics of NST-628 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Scientia Clinical Research, Ltd status: RECRUITING city: Rand state: New South Wales zip: 2031 country: Australia name: Shiena Lemin role: CONTACT phone: +61 2 9382 5800 email: ethics@scientiaclinicalresearch.com.au name: Charlotte Lemech, MD role: PRINCIPAL_INVESTIGATOR lat: -35.60079 lon: 146.62354 facility: Southern Oncology Research Unit status: NOT_YET_RECRUITING city: Adelaide zip: 5042 country: Australia name: Meggan O'Riley role: CONTACT email: Meggan.ORiley@socru.org.au name: Ganessan Kichenadasse, MD role: PRINCIPAL_INVESTIGATOR lat: -34.92866 lon: 138.59863 hasResults: False
nctId: NCT06326398 id: 3D moulage briefTitle: The Effect of Using 3D Printers and Moulage on Improving Stoma Care overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-05-01 date: 2024-10-01 date: 2024-03-22 date: 2024-03-25 name: Namik Kemal University class: OTHER name: TÜBİTAK briefSummary: When studies in the literature are examined, there are studies in which various methods are applied to students' stoma care knowledge and skills. Additionally, it is seen that there are studies using moulage or 3D printers as simulation applications in nursing education. However, there is no study on high-reality simulation application using 3D printer and moulage technique together.nIn this research, the effect of the stoma created with a 3D printer in a high-reality simulation on the stoma care knowledge and skills, satisfaction and self-confidence of nursing students will be examined by using the moulage technique. In addition, this application will be compared with nursing students' stoma care practices in the stoma model, which is classified as low-reality simulation. We think that our project will be unique in this field, as it uses current technological methods together in this planned research and is different from similar studies. conditions: Stoma Colostomy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 76 type: ESTIMATED name: Stoma Care measure: Knowledge Level Evaluation Form Regarding Stoma Care measure: Stoma Care Skill Grading Key measure: Student Satisfaction and Self-Confidence Scale in Learning sex: ALL minimumAge: 18 Years maximumAge: 22 Years stdAges: ADULT hasResults: False
nctId: NCT06326385 id: 53244021 briefTitle: Machine Learning Predictive Models for Sepsis Risk in ICU Patients With Intracerebral Hemorrhage overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2024-05-01 date: 2024-05-30 date: 2024-03-22 date: 2024-03-25 name: Xiangya Hospital of Central South University class: OTHER briefSummary: Patients with intracerebral hemorrhage (ICH) in the intensive care unit (ICU) are at heightened risk of developing sepsis, significantly increasing mortality and healthcare burden. Currently, there is a lack of effective tools for the early prediction of sepsis in ICH patients within the ICU. This study aims to develop a reliable predictive model using machine learning techniques to assist clinicians in the early identification of patients at high risk and to facilitate timely intervention.
This study aims to establish and validate multiple machine learning models to predict the onset of sepsis in ICU patients with ICH and to identify the model with the optimal predictive performance. conditions: Intracerebral Hemorrhage conditions: Sepsis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1800 type: ESTIMATED name: no intervention measure: Occurrence of sepsis sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Le Zhang city: Changsha state: Hunan zip: 410008 country: China name: Le Zhang role: CONTACT phone: 13973187150 email: zlzdzlzd@csu.edu.cn name: Ye Li role: CONTACT phone: 19967131289 email: 17670516318@163.com lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06326372 id: Delirium briefTitle: The Effect of Intraoperative Hyperoxemia on Postoperative Delirium in Geriatric Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2024-06-20 date: 2024-07-01 date: 2024-03-22 date: 2024-03-28 name: Tepecik Training and Research Hospital class: OTHER briefSummary: Oxygen therapy is the most common treatment modality for patients with hypoxemia, but target values for normoxemia are not clearly defined. Therefore, iatrogenic hyperoxemia is a very common situation. Even though there are many side effects reported related to hyperoxemia and hyperoxemia is shown to be related to worse outcome than expected; clinicians still observe hyperoxemia frequently.
Oxygen reserve index (ORi™) (Masimo Corp., Irvine, USA) can guide clinicians in detection of hyperoxia. ORi is a parameter which can evaluate partial pressure of oxygen (PaO2) rating from 0 to 1. There are growing evidences in ORi that it might be helpful to reduce hyperoxia in general anesthesia. Continuous ORi monitoring can be used for detecting and preventing hyperoxia. The ability to perform FiO2 titration with ORi may be an appropriate monitoring management to prevent the harmful effects of hyperoxia.In this study, in patients who underwent major abdominal surgery; It was aimed to investigate the effectiveness of ORi-guided FiO2 titration in preventing hyperoxia. conditions: Hyperoxia conditions: Delirium in Old Age studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: control name: ORi+SpO2 measure: Correlation of FiO2 and ORi value measure: Correlation of ORi and Delirium measure: Correlation of FiO2 and delirium sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Aykut Saritaş city: İ̇zmi̇r zip: 35640 country: Turkey lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06326359 id: Soh-Med-24-02-03MD briefTitle: Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-10 date: 2026-10 date: 2024-03-22 date: 2024-03-22 name: Sohag University class: OTHER briefSummary: Evaluation of Safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia conditions: Androgenic Alopecia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: autologous stromal vascular fraction measure: hair density measure: hair shaft thickness sex: MALE minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06326346 id: AMC2401 briefTitle: GIST Oral Paclitaxel(Liporaxel) overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2027-03-31 date: 2027-03-31 date: 2024-03-22 date: 2024-03-27 name: Asan Medical Center class: OTHER briefSummary: The purpose of this study is to evaluate safety and efficacy of Liporaxel for patients with GIST who failed on prior standard treatments, including imatinib, sunitinib, and regorafenib, and with low P-glycoprotein expression. conditions: Gastrointestinal Stromal Tumors studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: Liporaxel measure: 16 week disease control rate measure: Progression-free survival measure: Overall survival measure: Objective response rate measure: Adverse event assessed by NCI-CTCAE Version 5.0 sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Asan Medical Center, University of Ulsan College of Medicine city: Seoul state: Songpagu zip: 138-736 country: Korea, Republic of name: Min-Hee Ryu, MD, PhD role: CONTACT phone: 82-2-3010-5936 email: miniryu@amc.seoul.kr name: Hyung-Don Kim, MD, PhD role: CONTACT phone: 82-2-3010-0236 email: kimhdmd@amc.seoul.kr lat: 37.566 lon: 126.9784 hasResults: False